479 related articles for article (PubMed ID: 8996128)
21. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study.
Perez CA; Matthay KK; Atkinson JB; Seeger RC; Shimada H; Haase GM; Stram DO; Gerbing RB; Lukens JN
J Clin Oncol; 2000 Jan; 18(1):18-26. PubMed ID: 10623689
[TBL] [Abstract][Full Text] [Related]
22. Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study.
Moreau LA; McGrady P; London WB; Shimada H; Cohn SL; Maris JM; Diller L; Look AT; George RE
Clin Cancer Res; 2006 Oct; 12(19):5693-7. PubMed ID: 17020972
[TBL] [Abstract][Full Text] [Related]
23. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
[TBL] [Abstract][Full Text] [Related]
24. The current contribution of molecular factors to risk estimation in neuroblastoma patients.
Berthold F; Sahin K; Hero B; Christiansen H; Gehring M; Harms D; Horz S; Lampert F; Schwab M; Terpe J
Eur J Cancer; 1997 Oct; 33(12):2092-7. PubMed ID: 9516860
[TBL] [Abstract][Full Text] [Related]
25. Analysis of candidate gene co-amplification with MYCN in neuroblastoma.
George RE; Kenyon R; McGuckin AG; Kohl N; Kogner P; Christiansen H; Pearson AD; Lunec J
Eur J Cancer; 1997 Oct; 33(12):2037-42. PubMed ID: 9516849
[TBL] [Abstract][Full Text] [Related]
26. Detection of MYCN amplification using blood plasma: noninvasive therapy evaluation and prediction of prognosis in neuroblastoma.
Kojima M; Hiyama E; Fukuba I; Yamaoka E; Ueda Y; Onitake Y; Kurihara S; Sueda T
Pediatr Surg Int; 2013 Nov; 29(11):1139-45. PubMed ID: 24022278
[TBL] [Abstract][Full Text] [Related]
27. Coamplification of DDX1 correlates with an improved survival probability in children with MYCN-amplified human neuroblastoma.
Weber A; Imisch P; Bergmann E; Christiansen H
J Clin Oncol; 2004 Jul; 22(13):2681-90. PubMed ID: 15226335
[TBL] [Abstract][Full Text] [Related]
28. Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French society of pediatric oncology.
Minard V; Hartmann O; Peyroulet MC; Michon J; Coze C; Defachelle AS; Lejars O; Perel Y; Bergeron C; Boutard P; Leverger G; Stephan JL; Thyss A; Chastagner P; Couillault G; Devalck C; Lutz P; Mechinaud F; Millot F; Plantaz D; Rialland X; Rubie H
Br J Cancer; 2000 Oct; 83(8):973-9. PubMed ID: 10993641
[TBL] [Abstract][Full Text] [Related]
29. MDM2 SNP309 genotype is associated with ferritin and LDH serum levels in children with stage 4 neuroblastoma.
Parodi S; Perfumo C; Garaventa A; Inga A; Mazzocco K; Defferrari R; Tonini GP; Fronza G; Haupt R
Pediatr Blood Cancer; 2010 Aug; 55(2):267-72. PubMed ID: 20232446
[TBL] [Abstract][Full Text] [Related]
30. Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group Study.
Alvarado CS; London WB; Look AT; Brodeur GM; Altmiller DH; Thorner PS; Joshi VV; Rowe ST; Nash MB; Smith EI; Castleberry RP; Cohn SL
J Pediatr Hematol Oncol; 2000; 22(3):197-205. PubMed ID: 10864050
[TBL] [Abstract][Full Text] [Related]
31. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification.
Kaneko M; Tsuchida Y; Mugishima H; Ohnuma N; Yamamoto K; Kawa K; Iwafuchi M; Sawada T; Suita S
J Pediatr Hematol Oncol; 2002 Nov; 24(8):613-21. PubMed ID: 12439032
[TBL] [Abstract][Full Text] [Related]
32. Metastatic neuroblastoma in infants: are survival rates excellent only within the stringent framework of clinical trials?
Di Cataldo A; Agodi A; Balaguer J; Garaventa A; Barchitta M; Segura V; Bianchi M; Castel V; Castellano A; Cesaro S; Couselo JM; Cruz O; D'Angelo P; De Bernardi B; Donat J; de Andoin NG; Hernandez MI; La Spina M; Lillo M; Lopez-Almaraz R; Luksch R; Mastrangelo S; Mateos E; Molina J; Moscheo C; Mura R; Porta F; Russo G; Tondo A; Torrent M; Vetrella S; Villegas JA; Viscardi E; Zanazzo GA; Cañete A
Clin Transl Oncol; 2017 Jan; 19(1):76-83. PubMed ID: 27041689
[TBL] [Abstract][Full Text] [Related]
33. Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology Group.
Kawano A; Hazard FK; Chiu B; Naranjo A; LaBarre B; London WB; Hogarty MD; Cohn SL; Maris JM; Park JR; Gastier-Foster JM; Ikegaki N; Shimada H
Am J Surg Pathol; 2021 Aug; 45(8):1075-1081. PubMed ID: 33739795
[TBL] [Abstract][Full Text] [Related]
34. Favorable histology, MYCN-amplified 4S neonatal neuroblastoma.
Chan EL; Harris RE; Emery KH; Gelfand MJ; Collins MH; Gruppo RA
Pediatr Blood Cancer; 2007 Apr; 48(4):479-82. PubMed ID: 16333837
[TBL] [Abstract][Full Text] [Related]
35. Relationship between histopathological features, MYCN amplification, and prognosis: a UKCCSG study. United Kingdom Children Cancer Study Group.
George RE; Variend S; Cullinane C; Cotterill SJ; McGuckin AG; Ellershaw C; Lunec J; Pearson AD;
Med Pediatr Oncol; 2001 Jan; 36(1):169-76. PubMed ID: 11464876
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of DNA di-tetraploidy in neuroblastoma.
Ladenstein R; Ambros IM; Pötschger U; Amann G; Urban C; Fink FM; Schmitt K; Jones R; Slociak M; Schilling F; Ritter J; Berthold F; Gadner H; Ambros PF
Med Pediatr Oncol; 2001 Jan; 36(1):83-92. PubMed ID: 11464912
[TBL] [Abstract][Full Text] [Related]
37. N-myc oncogene and urinary catecholamines in children with neuroblastoma.
Barontini M; Gutiérrez MI; Levin G; Mur N; Diez B
Med Pediatr Oncol; 1993; 21(7):499-504. PubMed ID: 8341218
[TBL] [Abstract][Full Text] [Related]
38. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification.
Raschellà G; Cesi V; Amendola R; Negroni A; Tanno B; Altavista P; Tonini GP; De Bernardi B; Calabretta B
Cancer Res; 1999 Jul; 59(14):3365-8. PubMed ID: 10416595
[TBL] [Abstract][Full Text] [Related]
39. Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database.
Bagatell R; Beck-Popovic M; London WB; Zhang Y; Pearson AD; Matthay KK; Monclair T; Ambros PF; Cohn SL;
J Clin Oncol; 2009 Jan; 27(3):365-70. PubMed ID: 19047282
[TBL] [Abstract][Full Text] [Related]
40. Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project.
Meany HJ; London WB; Ambros PF; Matthay KK; Monclair T; Simon T; Garaventa A; Berthold F; Nakagawara A; Cohn SL; Pearson AD; Park JR
Pediatr Blood Cancer; 2014 Nov; 61(11):1932-9. PubMed ID: 25044743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]